
393: A conversation with the 'godfather' of biotech
The Readout Loud
00:00
Structure Therapeutics' amylin drug results and caveats
Elaine Chen summarizes Structure's phase 2 amylin data, highlighting 16% on-treatment weight loss and high discontinuation concerns.
Play episode from 01:03
Transcript


